STOCK TITAN

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY):

Listing: Euronext Paris NYSE-EURONEXT
Compartment: Compartment C
ISIN code: FR0010609263, Ticker: MKEA
Website: www.maunakeatech.com

Date

Number of shares comprising

the capital in circulation (1)

Total number of voting rights

Gross Total (2)

Net Total (3)

June 30th, 2023

48,256,265

49,298,739

49,245,842

(1) Including 1,980 shares issued upon exercise of preferred stock.

(2) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.

(3) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.

***

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

NewCap - Investor Relations

Thomas Grojean

+33 (0)1 44 71 94 94

maunakea@newcap.eu

Source: Mauna Kea Technologies

MKEAY

OTC:MKEAY

MKEAY Rankings

MKEAY Latest News

MKEAY Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
France
Paris